Sangamo BioSciences Inc. (NASDAQ:SGMO) hit a new 52-week low on Wednesday . The company traded as low as $4.19 and last traded at $4.25, with a volume of 556,772 shares traded. The stock had previously closed at $4.40.

A number of equities research analysts recently weighed in on SGMO shares. Wells Fargo & Co. started coverage on Sangamo BioSciences in a research report on Tuesday, May 3rd. They set a “buy” rating on the stock. Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Sangamo BioSciences in a research report on Friday, May 6th. Jefferies Group restated a “buy” rating and set a $14.00 price objective on shares of Sangamo BioSciences in a research report on Thursday, June 9th. Zacks Investment Research lowered Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Finally, Janney Montgomery Scott lowered Sangamo BioSciences from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $15.00 to $8.00 in a research report on Thursday, August 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Sangamo BioSciences currently has an average rating of “Buy” and an average price target of $15.58.

The company’s 50 day moving average price is $5.35 and its 200-day moving average price is $5.89. The company’s market cap is $299.42 million.

Sangamo BioSciences (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.14. The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.38 million. Sangamo BioSciences’s revenue for the quarter was down 56.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.17) earnings per share. Equities research analysts expect that Sangamo BioSciences Inc. will post ($1.11) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Sangamo BioSciences stock. Schwab Charles Investment Management Inc. boosted its position in Sangamo BioSciences Inc. (NASDAQ:SGMO) by 25.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 254,000 shares of the biopharmaceutical company’s stock after buying an additional 52,171 shares during the period. Schwab Charles Investment Management Inc. owned about 0.36% of Sangamo BioSciences worth $2,320,000 at the end of the most recent reporting period.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.